Novo Nordisk A/S - Share repurchase programme
On 31 January 2008 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount of up to DKK 2 billion in the period from 31 January 2008 to 6
August 2008.
Since the announcement as of 16 June 2008, the following transactions
have been made under the programme:
Number of Average Transaction
shares purchase price value, DKK
Accumulated, last announcement 4,147,907 1,411,434,599
16 June 2008 45,000 301.8300 13,582,350
17 June 2008 45,000 301.6300 13,573,350
18 June 2008 45,000 306.1400 13,776,300
19 June 2008 45,000 308.2100 13,869,450
20 June 2008 45,000 305.4400 13,744,800
Accumulated, 2008 4,372,907 1,479,980,849
With the transactions stated above, Novo Nordisk owns a total of
16,301,430 treasury shares, corresponding to 2.6% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,300
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 38 / 2008